StemCells Inc picked up by Israeli medical devices firm

By Dan Stanton contact

- Last updated on GMT

Image: iStock/DigitalStorm
Image: iStock/DigitalStorm

Related tags: Stem cell

StemCells Inc has merged with Israeli medical devices firm Microbot Medical three months after terminating a Phase II trial of its HuCNS-SC human neural stem cells.

The merger was announced in an SEC filing​ on Friday, and will see stockholders for the Israeli medical device firm take 95% ownership of the newly combined company.

Financial details of the deal were not disclosed, and Microbot Medical COO Simon Sharon would not comment when contacted by this publication.

Stemcells has had a turbulent few months: In May, California-based cell therapy developer StemCells Inc announced it was terminating its Phase II Pathway Study using its neural stem cells in spinal cord injury on the basis of inconclusive results coupled with limited financial resources.

The news sent the share price down by around 80% to $0.57 and since then the price has remained below $1, leading to a written notice from the Nasdaq Stock Market in July notifying the firm that it was not in compliance with the requirements for continued inclusion on the Nasdaq Market.

It also drove the firm to announce it was winding down its operations, and late last month it struck a deal to exit its lease at a Newark, California facility through a one-off $800,000 settlement payment to its landlord BMR-Pacific Research Center.

Microbot Medical focuses on micro-robotics in the field of medical technologies, while StemCells makes HuCNS-SC human neural stem cells and had four programmes in development, including the trials for spinal cord injury.

It is not clear if these programmes will continue, or whether the new entity will continue to focus on stem cell manufacture and development.

However, the company will not be advancing with StemCells’ CEO Ian Massey or CFO Gregory Schiffman, both of which resigned from their roles, pocketing one-off lump sum compensation of $216,667 and $187,500 respectively.

Related topics: Markets & Regulations, Cell lines

Related news

Show more

Related products

show more

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers

Follow us

Products

View more

Webinars